Market Data
Market Cap₹2,299.28 Cr.
52W High₹317.1
Current Price₹249.1
52W Low₹163.7
Down from 52W High21.4 %
Face Value₹2
Performance
ROCE6.52 %
ROE0.6 %
EPS (TTM)₹7.09
EPS Prev Qtr₹-2.57
EPS Last Year₹-1
EBITDA Qtr₹6.49 Cr.
Book Value₹102
Financial Health
Debt/Equity1.16
Debt/Profit351.53
Total Assets₹2,593.27 Cr.
Dividend Yield0.08 %
Promoter Holding58.86 %
Earning Power1.31 %
Valuation
Stock P/E778.44
Industry P/E33.81
Price to Book2.45
Price to Sales1.23
Graham Number₹27.06
Key Metrics
Face Value
₹2
About Indoco Remedies Ltd
Healthcare · Pharmaceuticals
Indoco Remedies Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹2,299.28 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a substantial promoter holding of 58.86%, indicating strong management control.
- The company maintains a moderate debt-to-equity ratio of 0.96, suggesting a balanced capital structure.
Weaknesses
- The company has an extremely high P/E ratio of 793.13, indicating it may be overvalued relative to earnings.
- The P/B ratio of 2.29 suggests the market values the company at a premium compared to its book value.
- The ROCE of 6.61% is relatively low, indicating inefficient use of capital.
- The ROE of 0.3% is very low, reflecting poor return on shareholders' equity.
- The dividend yield is minimal at 0.08%, offering limited income to investors.
- Net profit of ₹3.1 Cr is significantly low compared to the revenue of ₹1873.14 Cr, indicating thin profitability.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 484.67 | 445.36 | 475.61 | 467.5 |
| ↳ QoQ Growth | - | -8.1% | +6.8% | -1.7% |
| Expenses | 473.87 | 445.86 | 458.39 | 461.01 |
| Operating Profit | 10.8 | -0.5 | 17.22 | 6.49 |
| OPM % | 2.23% | -0.11% | 3.62% | 1.39% |
| Other Income | 0.76 | 0.98 | -0.04 | 2.18 |
| Interest | 24.56 | 25.64 | 45.92 | 28.29 |
| Depreciation | 32.25 | 32.01 | 32.49 | 34.53 |
| EBITDA | 43.05 | 31.51 | 49.71 | 41.02 |
| EBITDA Margin % | 8.88% | 7.08% | 10.45% | 8.77% |
| Profit Before Tax | -13.53 | -31.31 | -25 | 77.72 |
| Tax % | 31.93% | 5.94% | 5.28% | 15.8% |
| Net Profit | -9.21 | -29.45 | -23.68 | 65.44 |
| ↳ QoQ Growth | - | -219.8% | +19.6% | +376.4% |
| EPS | -1 | -3.2 | -2.57 | 7.09 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 18.4496 | 18.46 |
| Reserves | 1003.5468 | 920.82 |
| Borrowings | 978.03 | 1089.75 |
| Other Liabilities | 429.89 | 564.24 |
| Total Liabilities | 2429.9136 | 2593.27 |
| Fixed Assets | 1041.3009 | 1053.9 |
| CWIP | 276.1196 | 28.29 |
| Investments | 1.46 | 1.46 |
| Other Assets | 1111.03 | 1509.62 |
| Total Assets | 2429.9136 | 2593.27 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 94.9274 |
| Cash from Investing Activity | -339.1106 |
| Cash from Financing Activity | 241.4239 |
| Net Cash Flow | -2.7593 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 58.9% | 58.9% | 58.86% | 58.86% |
| FIIs % | 1.25% | 1.1% | 0.94% | 1.27% |
| DIIs % | 18.16% | 18.15% | 18.15% | 17.68% |
| Public % | 16.4% | 16.48% | 16.56% | 16.68% |
| No. of Shareholders | 33,319 | 32,659 | 32,276 | 32,457 |
Major Shareholders (>1%)
- Spa Holdings Pvt LtdPromoter and Promoter Group19.86%
- Shanteri Investment Pvt LtdPromoter and Promoter Group17.18%
- Kare Family Private TrustPromoter and Promoter Group14.19%
- Nippon Life India Trustee Ltd A/c Nippon India Small Cap FundPublic Shareholding4.80%
As of 2026-06-30View all shareholders →